Trastuzumab 440mg
| Active Ingredient | Trastuzumab |
|---|---|
| Manufacturers | Mylan Pharmaceuticals |
| Indications | Breast cancer, Stomach cancer |
| Strength | 440mg |
| Packaging | 1 Injection in 1 vial |
| Delivery Time | 6 To 15 days |
Trastuzumab 440mg is a monoclonal antibody used as a targeted therapy for treating HER2-positive breast cancer and HER2-positive metastatic gastric cancer. It works by attaching to the HER2 receptor on cancer cells, blocking their growth and signaling the immune system to destroy them.
Trastuzumab is typically administered via intravenous infusion and may be used alone or in combination with other chemotherapy drugs, depending on the treatment plan. This therapy is known to significantly improve survival rates in patients with HER2-positive tumors.
Note: Trastuzumab should be administered under the supervision of an oncologist in a clinical setting. Regular heart function monitoring is required during treatment.









There are no reviews yet.